Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models

BACKGROUND: Antibody-drug conjugates (ADCs) are an emerging technology consisting of an antibody, linker, and toxic agent, which have the potential to offer a targeted therapeutic approach. A novel target recently explored for the treatment of pancreatic cancer is guanylyl cyclase C (GCC). The objec...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Drugs
Hauptverfasser: Schreiber, Anna R., Nguyen, Anna, Bagby, Stacey M., Arcaroli, John J., Yacob, Betelehem W., Quackenbush, Kevin, Guy, Joe L., Crowell, Thomas, Stringer, Bradley, Danaee, Hadi, Kalebic, Thea, Messersmith, Wells A., Pitts, Todd M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6324574/
https://ncbi.nlm.nih.gov/pubmed/30631747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/2212697X05666180516120907
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge